STOCK TITAN

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ADC Therapeutics (NYSE: ADCT) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's CEO, Ameet Mallik, will deliver a company overview presentation on Tuesday, April 8, 2025, at 8:00 a.m. ET.

Investors and interested parties can access the live webcast through the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com. A replay of the presentation will remain available for approximately 30 days following the event.

ADC Therapeutics (NYSE: ADCT) ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale Annuale sulla Salute di Needham. Il CEO dell'azienda, Ameet Mallik, presenterà una panoramica dell'azienda martedì 8 aprile 2025, alle 8:00 a.m. ET.

Investitori e parti interessate possono accedere alla diretta web attraverso la pagina Eventi & Presentazioni nella sezione Investitori del sito web di ADC Therapeutics all'indirizzo ir.adctherapeutics.com. Una registrazione della presentazione sarà disponibile per circa 30 giorni dopo l'evento.

ADC Therapeutics (NYSE: ADCT) ha anunciado su participación en la próxima 24ª Conferencia Virtual Anual de Salud de Needham. El CEO de la compañía, Ameet Mallik, presentará una visión general de la empresa el martes 8 de abril de 2025, a las 8:00 a.m. ET.

Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la página de Eventos y Presentaciones en la sección de Inversores del sitio web de ADC Therapeutics en ir.adctherapeutics.com. Una repetición de la presentación estará disponible durante aproximadamente 30 días después del evento.

ADC Therapeutics (NYSE: ADCT)는 다가오는 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Ameet Mallik2025년 4월 8일 화요일 오전 8시(ET)에 회사 개요 발표를 할 예정입니다.

투자자 및 관심 있는 당사자는 ADC Therapeutics 웹사이트의 투자자 섹션에 있는 이벤트 및 발표 페이지를 통해 라이브 웹캐스트에 접근할 수 있습니다. 발표의 재생은 행사 후 약 30일 동안 이용 가능합니다.

ADC Therapeutics (NYSE: ADCT) a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle de Santé de Needham. Le PDG de l'entreprise, Ameet Mallik, présentera un aperçu de l'entreprise le mardi 8 avril 2025, à 8h00 ET.

Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la page Événements & Présentations dans la section Investisseurs du site Web d'ADC Therapeutics à l'adresse ir.adctherapeutics.com. Un replay de la présentation sera disponible pendant environ 30 jours après l'événement.

ADC Therapeutics (NYSE: ADCT) hat seine Teilnahme an der bevorstehenden 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt. Der CEO des Unternehmens, Ameet Mallik, wird am Dienstag, den 8. April 2025, um 8:00 Uhr ET eine Unternehmensübersicht präsentieren.

Investoren und interessierte Parteien können über die Seite Veranstaltungen & Präsentationen im Investorenbereich der Website von ADC Therapeutics unter ir.adctherapeutics.com auf den Live-Webcast zugreifen. Eine Wiederholung der Präsentation wird etwa 30 Tage nach der Veranstaltung verfügbar sein.

Positive
  • None.
Negative
  • None.

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing and future results of the Company's early research in exatecan-based Claudin-6, PSMA and ASCT2-targeting antibody-drug conjugates; the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7 and ADCT 602; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302416101.html

SOURCE ADC Therapeutics SA

FAQ

When is ADC Therapeutics (ADCT) presenting at the Needham Healthcare Conference 2025?

ADC Therapeutics will present on Tuesday, April 8, 2025, at 8:00 a.m. ET during the 24th Annual Needham Virtual Healthcare Conference.

How can investors watch ADC Therapeutics' (ADCT) Needham Conference presentation?

Investors can watch the live webcast through the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com.

How long will the replay of ADCT's Needham Conference presentation be available?

The webcast replay will be available for approximately 30 days after the presentation.

Who will be presenting for ADC Therapeutics (ADCT) at the 2025 Needham Healthcare Conference?

Ameet Mallik, Chief Executive Officer of ADC Therapeutics, will present the company overview.
Adc Therapeutics Sa

NYSE:ADCT

ADCT Rankings

ADCT Latest News

ADCT Stock Data

117.91M
71.77M
20.64%
63.17%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
Switzerland
EPALINGES